The family of matrix metalloproteinases (MMPs) has been identified as a key modulator in extracellular matrix remodeling, which is a hallmark of pathologic conditions such as cancer, atherosclerosis, and heart failure (1) (2) (3) (4) . The recognition of MMPs as disease biomarkers has stimulated the development of imaging strategies targeting these proteases, aiming for improved diagnosis or application in image-guided surgery. Commonly used approaches for MMP imaging are based on targeting with antibodies or smallmolecule ligands (5) (6) (7) (8) (9) . For example, radiolabeled MMP binding ligands have been developed for the detection of upregulated MMP levels by means of SPECT or PET (10) (11) (12) . Other strategies for MMP imaging, which do take full advantage of the nature of the target, are directed at the activity of the enzyme and will provide a selective readout of the activated MMP subpopulation and, importantly, lead to signal amplification because a single MMP can continuously activate its substrate (13) . Recently, a variety of substrate-flanked fluorescence resonance energy-transfer probes has been developed to sense MMP activity in living organisms (14) (15) (16) (17) (18) . Typically, these smart probes consist of one or multiple intramolecularly quenched fluorophores that become fluorescent on activation. With the exception of optical-guided interventions, these probes are unfortunately of limited clinical use for general imaging-based diagnostics.
Other protease-activatable imaging strategies that are not restricted to any one imaging modality have used probes that accumulated in MMP-rich tissue by hydrophobic clustering, cellular tagging, or cellular penetration on activation by MMP (19) (20) (21) . The latter strategy centered on an activatable cell-penetrating peptide (ACPP) that consisted of a matrix metalloproteinase-2 and -9 (MMP-2/9) substrate inserted between a polyanionic peptide and polycationic cell-penetrating peptide (CPP) conjugated to an imaging label. The cell-penetrating property of the polycationic peptide was quenched by electrostatic interactions with the polyanionic domain, preventing cellular uptake of the probe (22) . Cleavage of the substrate by MMP-2/9 released the polycationic from the polyanionic domain, thereby triggering cellular adhesion and subsequent uptake of the imaging label-functionalized polycationic peptide. A 3-to 4-fold increase in tumor homing was observed for ACPPs, compared with MMP-2/9 uncleavable control peptides, accompanied by a 4-fold-higher ACPP retention in tumor than in muscle (21) (22) (23) . Although ACPPs were successfully used for optical imaging and MRI of MMP-2/9 (21-25), the use of this concept in nuclear imaging or therapy has remained largely unexplored. Recently Watkins et al. investigated an MMP-14-activatable analog for SPECT (26) . Although in vitro activation was observed in cell cultures expressing MMP-14, a control cell line lacking MMP-14 expression also activated the probe, and therefore MMP-14 selectivity could not be demonstrated. In this work, we explored the use of radiolabeled ACPPs (Fig. 1A) for later application in SPECT or potentially PET of MMP-2/9 expression in tumors. The MMP-2/9-selective sequence in our study was used earlier by Jiang et al. (21) . The polycationic and polyanionic domains consisted of D-amino acids to avoid proteolytic degradation of these domains. The CPP domain of ACPP was functionalized with a DOTA chelate and radiolabeled with 177 Lu. The ACPP was then studied in vitro in MMP-2/ 9-positive HT-1080 fibrosarcoma cell cultures and in vivo in HT-1080 tumor-bearing mice together with a 177 Luradiolabeled nonactivatable CPP (non-ACPP) serving as a negative control and CPP without the polyanionic domain as a positive control (Fig. 1B) . For further insights into the mode of action of ACPP, we also developed dual-isotopelabeled analogs for the MMP activatable and nonactivatable probes (dACPP and non-dACPP, respectively) (Fig. 1B) . The dual-isotope approach allowed us to discriminate between activated ACPP and uncleaved ACPP as well as aspecific tissue uptake of the negative control in healthy and tumor-bearing mice.
MATERIALS AND METHODS

Materials
All reagents and solvents were obtained from commercial sources (Sigma-Aldrich and Biosolve) and used without further purification. 9-fluorenylmethyloxycarbonyl-protected amino acids and Rink amide resin were purchased from either Novabiochem (Merck) or Bachem. DOTA succinimidyl ester was obtained from Macrocyclics. Human recombinant enzymes were purchased from Calbiochem (Merck), Sigma, or R&D Systems. The enzymes were activated according to the vendor's protocols if needed. The labeling buffers were treated with Chelex-100 resin (BioRad Laboratories) overnight and passed through a 0.22-mm filter. IODO-GEN iodination tubes were purchased from Pierce Protein Research (Thermo Fischer Scientific). Tablets to prepare phosphate-buffered saline (PBS) (pH 7.4) were acquired from Calbiochem (Merck).
Probe Synthesis
Peptides Ac-e 9 -x-PLGLAG-r 9 -x-k(Mtt)-resin, Ac-e 9 -x-LALGPGr 9 -x-k(Mtt)-resin, Ac-y-e 9 -x-PLGLAG-r 9 -x-k(Mtt)-resin, Ac-y-e 9 -x-LALGPG-r 9 -x-k(Mtt)-resin, and Ac-LAG-r 9 -x-k(Mtt)-resin were synthesized on an automatic synthesizer (Prelude; Protein Technologies Inc.) by 9-fluorenylmethyloxycarbonyl solid-phase peptide synthesis using Rink amide resin (0.1 mmol), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate as the activating reagent, and N,N-diisopropylethylamine as a base. D-amino acids are denoted in lower case and x represents 6-aminohexanoic acid. The Mtt protecting group was selectively removed by incubating the peptides on resin with 1.8% v/v trifluoroacetic acid in dichloromethane with 2.0% v/v triisopropylsilane as a scavenger for 10 · 3 min, after which DOTA succinimidyl ester (1.5 equivalents) in N-methylpyrrolidone was added to the peptide resins and reacted overnight in the presence of N,N-diisopropylethylamine. The peptides were cleaved from the resin using a mixture of 96.0% v/v Enzyme ACCP Cleavage Assay dACPP or non-ACPP (0.1 mM) was incubated in triplicate with 5 nM human-recombinant MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-14, thrombin, plasmin, or urokinase in a mixture of 50 mM Tris, 200 mM NaCl, 10 mM CaCl 2 , and 10 mM ZnCl 2 at pH 7.5 at 700 revolutions per minute (rpm) and 37°C. After 1 h, the enzymes were quenched by the addition of trifluoroacetic acid (10% v/v). To determine the percentage cleaved peptide, the formation of the activated CPP domain was monitored by LC-MS and compared with a 100% cleaved reference sample (0.1 mM dACPP incubated with 30 nM MMP-2 for 1 h).
Animal Studies
All animal procedures were approved by the ethical review committee of the Maastricht University Hospital (The Netherlands) and were performed according to the principles of laboratory animal care (27) and the Dutch national law "Wet op Dierproeven" (Stb 1985, 336). Six-week-old athymic female mice (CD-1 nu/nu; body weight, 22-30 g; Charles River Laboratories) were housed in an enriched environment under standard conditions: 23°C-25°C, 50%-60% humidity, and 12-h light-dark cycles for more than 1 wk. Food and water were freely available.
Radiolabeling
For In Vitro Cell Assay. For In Vivo Studies. For 177 Lu-ACPP and 177 Lu-non-ACPP, 177 LuCl 3 in 0.05 M HCl (5.0 mL, 5.0 MBq) was mixed with ACPP or non-ACPP in MilliQ water (38.8 mL, 300 nmol) and metal-free 0.9% NaCl (450 mL) for 20 min at 300 rpm and 90°C. For 177 Lu/ 125 I-dACPP and 177 Lu/ 125 I-non-dACPP, 177 LuCl 3 in 0.05 M HCl (5.0 mL, 10.0 MBq) was mixed with dACPP or non-dACPP in MilliQ water (38.8 mL, 300 nmol) and metal-free 0.9% NaCl (450 mL) for 20 min at 300 rpm and 90°C. 125 I (PerkinElmer) in 1 mM NaOH (5.0 mL, 2.5 MBq) was mixed with dACPP or non-dACPP in MilliQ water (38.8 mL, 300 nmol) and PBS (225 mL) in an IODO-GEN iodination tube for 7 min at 300 rpm and 25°C and transferred to a siliconized 1.5-mL tube together with 250 mL of 0.9% NaCl. For 177 Lu-CPP, 177 LuCl 3 in 0.05 M HCl (5.0 mL, 5.0 MBq) was mixed with CPP in MilliQ water (31.5 mL, 300 nmol) and metalfree 0.9% NaCl (450 mL) for 20 min at 300 rpm and 90°C.
The 177 Lu and 125 I labeling yields were determined by radio-thinlayer chromatography, using instant thin-layer chromatography silica gel strips (Pall) eluted with 200 mM ethylenediaminetetraacetic acid in 0.9% NaCl and 20 mM citric acid at pH 5.2, respectively. The yields were imaged on a phosphor imager (FLA-7000; Fujifilm) and quantified with AIDA Image Analyzer software. Analytic radio-HPLC was performed on an Agilent 1100 system equipped with a C18 Eclipse XBD column (150 · 4.6 mm; particle size, 5 mm) and a Gabi radioactive detector (Raytest). The radiochemical purities were 95% or higher and typically at least 98%. 177 Lu-labeled dACPP was mixed with 125 I-labeled dACPP in a 1:1 molar ratio.
Cell Culture
HT-1080 fibrosarcoma cells acquired from the American Type Culture Collection were maintained under standard culture conditions in Eagle's minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), penicillin (100 U/mL), streptomycin (100 mg/mL), and 2 mM Glutamax (Gibco).
In Vitro Cell Incubation with Radiolabeled ACPP Probes
177 Lu-ACPP was activated before cell incubation with recombinant-human MMP-2 (10 pmol) for 3 h in 50 mM Tris, 200 mM NaCl, 10 mM CaCl 2 , and 10 mM ZnCl 2 at pH 7.5, as was assessed by reversed-phase HPLC. HT-1080 cells were cultured in poly-Dlysine-coated 12-well plates. At 80% confluency, cells were washed twice with Dulbecco's PBS (Gibco) and once with serum-free medium and subsequently incubated in triplicate with 1.25 mM 177 Lu-non-ACPP, 1.25 mM uncleaved 177 Lu-ACPP, 1.25 mM precleaved 177 Lu-ACPP, and 1.25 mM 177 Lu-CPP (19.3 mL/ 1.25 nmol of probe, 0.5 MBq of 177 Lu) in serum-free medium (981 mL). After 3 h of incubation, cells were washed 5 times with Dulbecco's PBS and harvested by trypsination (0.25% w/v trypsin-ethylenediaminetetraacetic acid [Gibco] ). The trypsin activity was inhibited by addition of MEM, after which the cells were isolated by centrifugation (1,000 rpm, 10 min, room temperature). Cell pellets and all wash fractions were analyzed for 177 Lu radioactivity (115-270 keV) by a g-counter (Wizard 1480; PerkinElmer).
HT-1080 Fibrosarcoma Model
HT-1080 cells at 80%-90% confluency were harvested by trypsination. The trypsin activity was inhibited by the addition of MEM, after which cells were isolated by centrifugation. The cells were washed once with sterile Dulbecco's PBS and concentrated to 3.0 · 10 7 cells/mL. Approximately 3.0 · 10 6 HT-1080 cells (in 100 mL of sterile Dulbecco's PBS) were injected per mouse, subcutaneously on the left flank. The tumor sizes were determined by a ruler every 2 d, and their volumes were calculated using the formula 1/2 · l · b · h. When tumors reached 8-30 mm 3 (typically 1-2 wk after subcutaneous injection), the mice were used for in vivo studies.
Biodistribution Experiments
Biodistribution experiments were performed on tumor-bearing mice (n 5 3) or tumor-free healthy mice (n 5 4) by intravenous injection of 177 Lu-ACPP (60 nmol/100 mL, ;1.0 MBq), 177 Lunon-ACPP (60 nmol/100 mL, ;1.0 MBq), 177 Lu/ 125 I-dACPP (60 nmol/100 mL, ;1.0 MBq of 177 Lu and ;0.25 MBq of 125 I), 177 
injection, subjected to cardiac puncture, and sacrificed by cervical dislocation. Organs and tissues of interest were harvested and weighed, after which the radioactivity of the samples was measured in a g-counter along with standards to determine the injected dose per gram (%ID/g). The energy windows were set to 10-80 keV for 125 I and 155-380 keV for 177 Lu.
Blood Kinetic Measurements Plus Biodistribution Experiments
Tumor-bearing mice (n 5 3) were intravenously injected with 177 Lu-ACPP (60 nmol/100 mL, ;1.0 MBq), 177 Lu-non-ACPP (60 nmol/100 mL, ;1.0 MBq), 177 Lu/ 125 I-dACPP (60 nmol/100 mL, ;1.0 MBq of 177 Lu and ;0.25 MBq of 125 I), 177 Lu/ 125 I-nondACPP (60 nmol/100 mL, ;1.0 MBq of 177 Lu and ;0.25 MBq of 125 I), or 177 Lu-CPP (60 nmol/100 mL, ;1.0 MBq). At selected time points (2, 5, 10, and 30 min and 1 and 3 h), blood samples were withdrawn from the vena saphena, weighed, and diluted to 1 mL with MilliQ water. The mice were anesthetized with isoflurane 24 h after intravenous injection, subjected to cardiac puncture, and sacrificed by cervical dislocation. Organs and tissues of interest were harvested and weighed, after which the radioactivity was measured for all samples in a g-counter along with standards to determine the %ID/g. The probe concentration at time 0 (C 0 ) was calculated by fitting the blood clearance curves to a 2-phase exponential decay for ACPP, non-ACPP, dACPP, and non-dACPP and to a 1-phase exponential decay for CPP. The volume of distribution per mouse was calculated using the formula V D 5 dose/(body weight · C 0 ) [L/kg].
Gelatin Zymography
Methods for gelatin zymography are described in the supplemental materials.
Statistical Methods
Quantitative data were expressed as mean 6 SD. The means of the groups were compared by the parametric Welch's t test (28) . Because of the relatively small sample sizes per group (n 5 4-6), the nonparametric Mann-Whitney U test was also performed. All tests were 2-tailed, and P values of less than 0.05 indicate significant differences.
RESULTS
In Vitro Studies
The sensitivity of the ACPP structure toward 9 different enzymes (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-14, urokinase, plasmin, and thrombin) was studied in vitro. LC-MS analysis after 1 h of incubation showed that ACPP is efficiently cleaved between the glycine and leucine residue by MMP-2, MMP-9, and, to a minor extent, MMP-14, whereas no ACPP cleavage was observed for the other enzymes (Fig. 2) . Under similar conditions, MMP-2 was not able to cleave the negative-control peptide non-ACPP (Supplemental Fig. 2) .
Next, we radiolabeled the polycationic domain of ACPP with 177 Lu (Supplemental Figs. 3 and 4) and set out to assess the uptake of 177 Lu-ACPP by MMP-positive HT-1080 cells. Although these cells secrete MMP-2 and MMP-9, as was evidenced by gelatin zymography (Supplemental Fig. 5 ), it has been demonstrated that those enzymes become too diluted in 2-dimensional cell culture supernatants, resulting in minimal ACPP probe activation and insignificant uptake (22) . Therefore, 177 Lu-ACPP was precleaved with MMP-2 (resulting in 85% activation, Supplemental Fig. 6 ), incubated for 3 h at 1.25 mM with HT-1080 cells, and compared with 177 Lu-non-ACPP, uncleaved 177 Lu-ACPP, and 177 Lu-CPP. The cellular uptake of the activated ACPP was comparable to the uptake of the positive control, taking the 85% activation of ACPP into account, whereas uncleaved ACPP showed negligible cellular uptake (Fig. 3) . peptide non-ACPP (60 nmol, intravenous injection) in MMP-2/9-positive HT-1080 tumor-bearing mice ( Fig. 4 ; Supplemental Table 1 ). Table 1 shows the statistical analysis of the biodistribution data. The tumor uptake of 177 Lu-ACPP was significantly higher compared with its accumulation in muscle and with the tumor uptake of 177 Lu-non-ACPP after 6 and 24 h, supporting earlier studies proposing ACPP activation by tumoral MMP-2/9 (21) (22) (23) . Surprisingly, however, not only the tumor but also other tissues showed significantly higher retention of 177 Lu-ACPP than of 177 Lu-non-ACPP. In the muscle and heart, the relative difference between 177 Lu-ACPP and 177 Lu-non-ACPP retention was even higher than that observed for tumors (Supplemental Table 1 ), although no MMP-2/9 activity was detected by gelatin zymography in these tissues (Supplemental Fig. 5 ). Furthermore, 177 Lu-non-ACPP displayed a significantly higher tumor retention than muscle and heart retention. A high liver, spleen, and kidney retention was observed for 177 Lu-ACPP, whereas 177 Lu-non-ACPP accumulated mainly in the kidneys, indicating that the probes are excreted via different pathways. As CPPs have been reported to mainly distribute to the liver (22, 29) , the altered biodistribution may have been caused by enzymatic conversion of 177 Lu-ACPP into 177 Lu-CPP. The biodistribution data obtained with ACPP do not, however, allow discrimination between retention of uncleaved ACPP and the MMP cleavage product CPP. In principle, the differences found in the tissue accumulation of ACPP and non-ACPP could originate from aspecific accumulation instead of tumoral MMP-related activation.
To address this open question and to unravel the activation process of ACPP (i.e., does ACPP activation takes place and, if so, where?), we developed dual-isotope-radiolabeled analogs (dACPPs) (Fig. 1B) , in which the polycationic CPP and polyanionic peptide were labeled with the orthogonal radioisotopes 177 Lu (energy of g-ray emitted by isotope [E g ] 5 208 keV) and 125 I (E g 5 35 keV), respectively (Supplemental Figs. 3 and 4) . A large ratio of 177 Lu over 125 I would indicate cleavage of the probe and subsequent retention of the 177 Lu-radiolabeled CPP. The in vivo biodistribution of the dual-isotope probe 177 Lu/ 125 IdACPP 24 h after intravenous injection showed an approximately 10-to 50-fold-higher retention of 177 Lu than 125 I in the tumor, muscle, heart, lung, and spleen ( Fig. 5A ; Supplemental Table 3 ). For 177 Lu/ 125 I-non-dACPP, the tissue retention of 177 Lu was only slightly higher-that is, approximately 2-to 3-fold-than that of 125 I (Fig. 5B) . Furthermore, the biodistribution of 177 Lu/ 125 I-dACPP showed a high accumulation of 177 Lu in the liver, whereas 125 I retention was minimal. An in vivo biodistribution study of 177 Lu/ 125 I-dACPP in tumor-free healthy mice was also performed, which showed the same 10-to 50-fold-higher retention levels of 177 Lu relative to 125 I in various tissues as was observed in tumor-bearing mice ( Fig. 5C ; Supplemental Table 3 ), suggesting that the dACPP activation is not caused by tumorassociated MMP-2/9.
In Vivo Biodistribution of Radiolabeled CPP
The in vivo biodistribution of 177 Lu-CPP ( Fig. 4 ; Supplemental Table 1 ), the activated CPP domain of ACPP serving as a positive control, revealed significantly higher tumor retention levels than muscle and heart retention. Comparison of the tumor-to-tissue ratios for 177 Lu-ACPP and 177 Lu-CPP showed no significant differences ( Fig. 6 ; Table  1 ; Supplemental Table 2 ), indicating that ACPP was most likely activated in the vascular compartment.
Blood Kinetic Profiles
177 Lu/ 125 I-dACPP showed a faster blood clearance of 177 Lu than 125 I (Fig. 7B) , pointing to dACPP activation and subsequent tissue trapping of 177 Lu-CPP, whereas comparable blood clearance rates were observed for 177 Lu and 125 I for mice injected with 177 Lu/ 125 I-non-ACPP (Fig. 7C) . We observed a 30-and 10-fold-higher blood concentration for 177 Lu-CPP (Supplemental Fig. 7 ) and 177 Lu-ACPP, respectively (Fig. 7A) , than for 177 Lu-non-ACPP at 3 h after injection, indicating the presence of activated CPP in blood for 177 Lu-ACPP at this time point. After 6 h, both ACPP and non-ACPP were essentially cleared from the circulation (Supplemental Table 1 ).
Determination of Volume of Distribution (V D )
The V D calculated from the blood clearance measurements is in the range of 0.27 , V D , 0.36 L/kg of body weight (V D values in L/kg are 0.36 6 0.19 for ACPP, 0.32 6 0.05 for non-ACPP, 0.27 6 0.17 for dACPP, and 0.29 6 0.08 for non-dACPP). The blood clearance measurements point toward a rapid distribution of these probes throughout the extracellular fluids in the whole body, without cell membrane crossing but with some binding to compounds and cell surfaces in the extracellular, extravascular space (30) . The V D for 177 Lu-CPP was found to be 4-foldhigher (1.28 6 0.21 L/kg), suggesting that a significant amount of the highly positively charged polypeptide directly binds to cells in the extravascular, extracellular space and to endothelial cells in the vascular space. In this respect, CPP will probably have a high tendency to bind to circulating cells as well, which would explain the relatively high blood levels of CPP observed at later time points (Supplemental Fig. 7 ). Alternatively, a slow desorption of the polycationic peptide and subsequent transport back into the circulation is a reasonable explanation for the observed prolonged blood clearance profile (22) .
DISCUSSION
The use of activatable cell-penetrating imaging probes has been advocated as a promising general strategy for the in vivo imaging of proteolytic activity, in particular in tumors (21, 31) . Several recent reports have asserted that tumors can be visualized via optical imaging and MRI of MMP-2/9 activity using ACPPs (21) (22) (23) (24) (25) . An analogous radiolabeled ACPP probe for PET or SPECT would allow clinical translation to sensitive whole-body diagnostic imaging while avoiding potential toxicity risks associated with gadolinium uptake and retention in cells and organs. Therefore, we set our sights on the development of radiolabeled ACPPs consisting of an MMP-2/9-sensitive peptide linker. In accordance with the results for a Cy-5-conjugated MMP-2/9-cleavable ACPP (21, 22) , we showed that the radiolabeled ACPPs can efficiently be activated by MMP-2/9 in vitro (Figs. 2 and 3) . The in vivo biodistribution of a 177 Lu-radiolabeled ACPP and a negative-control non-ACPP containing a scrambled linker was assessed in mice bearing MMP-2/9-positive tumors ( Fig. 4 ; Supplemental Tables 1  and 2 ). We found for the ACPP a high uptake in the tumor, compared with muscle or heart, but an even higher uptake in the spleen, liver, and kidney. For the tumor, ACPP exhibited a 6-fold-higher retention than non-ACPP-a slightly higher retention than reported by Jiang et al. At a first glance, this higher retention seems to support ACPP sensitivity toward tumoral MMP-2/9, but surprisingly, the retention ratios for ACPP over non-ACPP were higher in many tissues than the ratio found for the tumor. For example, the ACPP retention in muscle is 12-fold higher than non-ACPP, despite the fact that MMP-2/9 activity in muscle was not detected by gelatin zymography (Supplemental Fig. 5 ). Dual-isotope-labeled ACPPs, in which the polycationic CPP was labeled with 177 Lu and the polyanionic domain was labeled with 125 I, revealed 177 Lu-to-125 I tissue ratios of 10:50 in tumor, muscle, heart, lung, and spleen, indicating that ACPP had been activated and subsequently retained in all tissues as 177 Lu-CPP ( Table 3 ). Similar 177 Lu-to-125 I ratios were observed in muscle, heart, lung, and spleen when dACPP was administrated to healthy mice. The negative control, on the other hand, showed modest 177 Lu-to-125 I tissue ratios of 2 to 3, possibly caused by activation by aspecific proteolytic degradation of the linker around one of the flexible glycine residues. The iodinated probes were not subject to significant dehalogenation, as evidenced by the low amount of 125 I measured in thyroids and the stomach (Supplemental Table 3 ). The biodistribution and blood clearance experiments for the various probes compellingly show that the used ACPP is taken up and retained in all tissues in its activated form, even in the absence of an MMP-expressing tumor (Fig. 5C ). These findings do not support tumor-associated MMP-2/9 cleavage of ACPP as the main mechanism for ACPP activation and subsequent tumor accumulation. Instead, the higher retention of the activated ACPP in tumor than in muscle is most likely due to tissue aspecific ACPP activation, resulting in increased accumulation of the activated probe in the tumor promoted by the enhanced permeability and retention effect in combination with high vascularization (32) . Further evidence for this assertion comes from the similar biodistribution profiles observed for 177 Lu-ACPP and the positive-control 177 Lu-CPP (Fig. 6 ). Passive uptake due to tumor leakiness will likely occur for any probe with a high free V D , including our negative-control peptide non-ACPP, explaining the significantly higher tumor uptake than muscle uptake of non-ACPP and the smaller relative difference in uptake between ACPP and non-ACPP in tumor, compared with muscle.
Interestingly, it was recently demonstrated that tumor retention of nanoparticles by the enhanced permeability and retention effect can be further increased by MMP-2/9-sensitive ACPP functionalization of the nanoparticles (24) . This study also showed that significantly higher muscle uptake was obtained for MMP-2-sensitive ACPP-labeled nanoparticles than for non-ACPP-labeled nanoparticles-a finding consistent with an activation of the nanoparticles in the vascular system and subsequent tissue aspecific uptake. The tumorto-muscle ratio for this MMP activatable nanoparticle was approximately 6, slightly higher than observed for the lowmolecular-weight MMP activatable peptides (23, 24) , indicating that the enhanced permeability and retention effect may play out favorably for larger activatable probes.
CONCLUSION
We have reported the first in vivo studies exploring the use of radiolabeled ACPPs for the detection of MMP activity in tumors. Activation of the radiolabeled ACPP indeed resulted in a strong enhancement of tumor retention in vivo, showing that the concept of ACPPs can be translated to nuclear applications. However, dual-isotope-labeled ACPPs and control experiments in healthy and tumor-bearing mice revealed that the activation of ACPP was tumorindependent. Most likely, probe activation occurred already in the vasculature, followed by aspecific tumor uptake. Therefore, several challenges need to be addressed to achieve clinical translation of ACPPs. First, the proteasesensitive linker should be carefully chosen to prevent aspecific cleavage. Second, highly specific accumulation in the tissue of interest may be achieved by ACPPs that are exclusively sensitive to cell membrane-bound enzymes that do not shed into the vasculature, thereby avoiding ACPP activation in the blood.
